GLP-1 Medications Beyond the Brand Name: Navigating Compounded Semaglutide, Telehealth Prescriptions, and What the FDA Actually Says

Few pharmaceutical categories have reshaped the American health conversation as rapidly as GLP-1 receptor agonists. Medications like semaglutide — marketed under the brand names Ozempic and Wegovy — and tirzepatide, sold as Mounjaro and Zepbound, have moved from specialty endocrinology practices into mainstream culture with remarkable speed. Waiting lists at traditional clinics stretch for months. Insurance coverage remains inconsistent and frequently contentious. Into that gap, an entire ecosystem of alternative sourcing channels has emerged: compounding pharmacies, telehealth-only prescribers, and international online vendors willing to ship without the friction of a conventional clinical encounter.

For patients who are genuinely struggling with obesity or type 2 diabetes and facing systemic barriers to access, this market may appear to offer a practical solution. But the regulatory landscape is more complicated — and the clinical risks more variable — than many promotional websites acknowledge.

What GLP-1 Receptor Agonists Actually Are

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a naturally occurring hormone involved in insulin secretion, appetite regulation, and gastric emptying. Originally developed to manage blood sugar levels in type 2 diabetes, these drugs demonstrated significant weight-loss effects in clinical trials, prompting FDA approval of higher-dose formulations specifically for chronic weight management.

Semaglutide is approved by the FDA under two distinct indications: Ozempic (lower dose, for type 2 diabetes) and Wegovy (higher dose, for chronic weight management in adults with obesity or overweight with at least one weight-related condition). Tirzepatide, which targets both GLP-1 and GIP receptors, follows a similar dual-approval structure with Mounjaro and Zepbound. These are prescription medications, not over-the-counter supplements — a distinction with significant regulatory and safety implications.

The Compounding Pharmacy Channel: What Changed and What It Means Now

During a period of significant supply shortages for both semaglutide and tirzepatide — which the FDA officially designated as drugs in shortage — federal regulations permitted compounding pharmacies to legally produce versions of these medications. Compounding pharmacies are state-licensed facilities that can prepare customized drug formulations, typically for patients with specific clinical needs that commercially available products cannot address.

The shortage designation created a temporary but expansive window. Hundreds of compounding pharmacies began producing injectable semaglutide, often at substantially lower price points than branded versions. Telehealth platforms proliferated to serve as prescribing intermediaries, allowing patients to obtain prescriptions through brief online consultations and have compounded medications shipped directly to their homes.

However, the FDA has since removed semaglutide from its drug shortage list, and as of early 2025, the agency has taken the position that compounding pharmacies may no longer legally produce copies of semaglutide for general patient populations. Tirzepatide remains in a more transitional regulatory state. This does not mean that all compounding operations have ceased — enforcement timelines and legal challenges have created continued ambiguity — but it does mean that patients ordering compounded semaglutide today may be doing so in a legally and clinically uncertain environment.

The Quality Control Question

Beyond the regulatory status of compounded GLP-1 medications lies a more fundamental concern: product quality. FDA-approved medications undergo rigorous manufacturing standards, including testing for potency, sterility, and the absence of contaminants. Compounded medications are not subject to the same pre-market review process.

The FDA has issued multiple warnings about compounded semaglutide products that were found to contain incorrect dosages, improper salt forms of the active ingredient (semaglutide sodium rather than the approved semaglutide base), or inadequate sterility. Some adverse event reports submitted to the agency have involved patients who experienced serious side effects — including hospitalizations — after using compounded versions.

This does not mean that every compounding pharmacy produces substandard products. Some operate under stringent quality protocols. But consumers have limited practical means of verifying that quality without independent laboratory testing, which is neither standard nor accessible for most patients.

Telehealth Prescribing: Convenient, but Not Without Caveats

The rise of telehealth has genuinely democratized access to medical consultations, including for weight management. Platforms offering GLP-1 prescriptions through asynchronous questionnaires or brief video calls can provide legitimate pathways for appropriate patients — particularly those in areas with limited specialist access.

However, the telehealth model introduces its own considerations. A thorough evaluation for GLP-1 therapy should include a review of cardiovascular history (there is a contraindication for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), assessment of gastrointestinal conditions, current medication review for interactions, and a frank discussion of realistic outcomes and side effect profiles.

Some telehealth platforms conduct genuinely thorough evaluations. Others have faced criticism — and in some cases, regulatory scrutiny — for cursory intake processes that prioritize speed of prescription over clinical rigor. Patients should be cautious of any platform that issues a prescription without asking detailed medical history questions or that does not offer follow-up clinical support during the titration period.

International Pharmacies: A Higher-Risk Proposition

Perhaps the most concerning channel in this ecosystem is the international online pharmacy market. Websites operating outside U.S. jurisdiction offer brand-name or generic versions of semaglutide at prices that significantly undercut domestic sources. Importing prescription medications for personal use from foreign sources is generally illegal under U.S. federal law, and the FDA does not verify the authenticity or safety of products sourced through these channels.

Counterfeit GLP-1 products have been documented. The agency has issued alerts about fraudulent injectable products falsely labeled as semaglutide that contained entirely different substances. Patients self-administering injectable medications of unknown provenance face risks that extend well beyond the known side effect profile of legitimate GLP-1 therapy.

Questions to Raise With Your Physician Before Proceeding

If you are considering GLP-1 therapy through any channel, the following questions represent a reasonable starting point for a clinical conversation:

• Am I an appropriate candidate? GLP-1 medications are indicated for specific patient populations. A physician should evaluate your BMI, comorbidities, and contraindications before prescribing.
• What is the source of the medication being prescribed? If a telehealth platform is prescribing compounded semaglutide, ask which compounding pharmacy they use and whether that pharmacy holds 503B outsourcing facility status — a higher federal regulatory standard.
• What monitoring will be in place? Appropriate GLP-1 prescribing includes follow-up for side effect management, dosage adjustment, and ongoing assessment of efficacy.
• What are the realistic expectations? Clinical trials show meaningful average weight loss with these medications, but individual results vary substantially, and discontinuation typically results in weight regain without concurrent lifestyle changes.

The Regulatory Horizon

The FDA is actively working to clarify and enforce its position on compounded GLP-1 medications, and the legal landscape will likely continue shifting throughout 2025 and beyond. Patients who began compounded therapy during the shortage period may find their access disrupted as enforcement tightens.

For those seeking legitimate access to GLP-1 therapy, the most reliable path remains a conventional clinical relationship with a licensed prescriber who can order FDA-approved branded medications and assist with insurance appeals or manufacturer savings programs — several of which offer meaningful cost reductions for eligible patients.

The promise of these medications is real. The shortcuts being marketed around them carry risks that deserve honest, clear-eyed evaluation before any order is placed.